FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036706858> ?p ?o ?g. }

• W3036706858 endingPage "102847" @default.
• W3036706858 startingPage "102847" @default.
• W3036706858 abstract "The pandemic of Coronavirus Disease 2019 (COVID-19) is rapidly evolving as a major threat to global health. Cardiovascular and metabolic comorbidities including hypertension, diabetes, coronary artery disease (CAD) are common among COVID-19 patients, and are associated with increased mortality and adverse outcomes in COVID-19 [[1]Clerkin KJ Fried JA Raikhelkar J et al.COVID-19 and cardiovascular disease.Circulation. 2020; 141: 1648-1655Crossref PubMed Scopus (1118) Google Scholar]. However, clinical or physiological evidence is lacking regarding the causal relationship between cardiovascular diseases and the severity of COVID-19, and whether management of cardiovascular risk factors would benefit the outcome of COVID-19. Mendelian randomization (MR) is a recently emerged strategy for assessing the causality between a disease and intermediate risk factors utilizing genetic variants as instrumental variables [[2]Emdin CA Khera AV Kathiresan S Mendelian randomization.JAMA. 2017; 318: 1925-1926Crossref PubMed Scopus (592) Google Scholar]. If the intermediate risk factor is indeed causal for the disease, the genetic variants specifically associated with the risk factor will also be associated with the disease of interest. Although MR can be conducted in a retrospective way, it is conceptually similar to prospective randomized controlled trials (RCT) (Fig. 1). Since the genetically determined risk factors occur prior to the disease onset, MR avoids the potential bias of reverse causation in retrospective studies, and the risk of confounding is also reduced by applying genetic instruments unassociated with known confounders of the disease through pleiotropic effects [[2]Emdin CA Khera AV Kathiresan S Mendelian randomization.JAMA. 2017; 318: 1925-1926Crossref PubMed Scopus (592) Google Scholar]. A potential important application of MR is to investigate whether cardiovascular risk factors such as hypertension, hyperlipidemia and diabetes are contributing causally to the poor outcome of COVID-19, by applying the instruments validated in previous MR studies [[3]Jansen H Samani NJ Schunkert H Mendelian randomization studies in coronary artery disease.Eur Heart J. 2014; 35: 1917-1924Crossref PubMed Scopus (147) Google Scholar]. Once the causal risk factors are identified, the interventions against these risk factors such as anti-hypertensive drugs, lipid-lowering drugs such as statins, and blood glucose control agents may be effective to ameliorate the disease progression of COVID-19. Notably, the causal estimates derived from MR may reflect the lifetime effects of the risk factors. It has been shown that the CAD protection effects of genetically lower low-density lipoprotein (LDL) and blood pressure are substantially greater than what has been observed in short-term RCTs of statin and antihypertensive drugs [[4]Assimes TL Roberts R Genetics: implications for prevention and management of coronary artery disease.J Am Coll Cardiol. 2016; 68: 2797-2818Crossref PubMed Scopus (77) Google Scholar]. Therefore, the results of MR may not recapitulate exactly the same degree of effects for short-term treatment during the acute phase of infection, but rather the effects of prevention and long-term treatment of the cardiovascular risk factors on the disease outcome. Importantly, most clinical trials currently ongoing are directed at treatment strategies and are not addressing the prevention of COVID-19 disease progression [[5]Bauchner H Fontanarosa PB Randomized clinical trials and COVID-19: managing expectations.JAMA. 2020; Crossref Scopus (73) Google Scholar]. If the control of cardiovascular risk factors is effective to reduce the risk of severe disease of COVID-19, the strengthened management of these risk factors and cardiovascular comorbidities in the area of high incidence of COVID-19 may protect those with underlying cardiovascular diseases from becoming severely ill once they are infected. Ultimately, these measures can be applicable for altering the incidence of severe cases and death rate of COVID-19 in the coming months and future. Another potential application of MR is to address controversies regarding the use of certain drugs in COVID-19 patients, including angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) [[6]Vaduganathan M Vardeny O Michel T McMurray JJV Pfeffer MA Solomon SD Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19.N Engl J Med. 2020; Crossref PubMed Scopus (1514) Google Scholar]. Preclinical studies suggested that ACEI/ARB may increase expression of ACE2, the functional receptor to SARS-CoV-2, which may in turn increase the susceptibility of the patients to the virus [[6]Vaduganathan M Vardeny O Michel T McMurray JJV Pfeffer MA Solomon SD Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19.N Engl J Med. 2020; Crossref PubMed Scopus (1514) Google Scholar]. Several recent retrospective observational cohort studies showed that the continued use of ACEI/ARB is unlikely to be harmful or may even be beneficial to COVID-19 patients with hypertension, but the effects of ACEI/ARB on the disease outcome await prospective studies to confirm [[7]Williams B Zhang Y Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19.Lancet. 2020; Summary Full Text Full Text PDF Scopus (31) Google Scholar]. This question can be investigated through MR in a more straightforward way, since MR is also able to predict the long-term therapeutic and side effects of a drug in human by manipulating the genetic variants of the drug-targeted proteins. Genetic variants of ACE and AGTR1, the genes encoding angiotensin-converting enzyme and angiotensin II receptor type 1, respectively, can be carefully selected and applied to construct the instrumental variables that mimic the effects of ACEI and ARB. Evaluating the phenotypes of the COVID-19 patients with genetically lowered expression of ACE or AGTR1 may shed light on the effects of long-term treatments of ACEI/ARB on the outcome of COVID-19. The power of MR can be extended to explore other host-modulated therapies that have defined genetic targets in human. In 2018, an MR study screened the association between the genetic determinants of 227 biomarkers and CAD, and identified serum CSF1 and CXCL12 as novel causal mediators of CAD [[8]Sjaarda J Gerstein H Chong M et al.Blood CSF1 and CXCL12 as causal mediators of coronary artery disease.J Am Coll Cardiol. 2018; 72: 300-310Crossref PubMed Scopus (62) Google Scholar]. Since CSF1 is known to be upregulated by IL-1β, this causal association is consistent with the protective effect of IL-1β antagonist canakinumab on CAD in the CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcome Study) [[8]Sjaarda J Gerstein H Chong M et al.Blood CSF1 and CXCL12 as causal mediators of coronary artery disease.J Am Coll Cardiol. 2018; 72: 300-310Crossref PubMed Scopus (62) Google Scholar]. Such a comprehensive screening approach could also be applied in COVID-19 patients to identify the biomarkers causally associated with disease severity, which may elucidate potential therapies for COVID-19. Interestingly, a recent MR study found tentative causal contributions of diabetes-related traits as well as several druggable blood proteins on increased ACE2 expression in lung tissue [[9]Rao S Lau A So HC Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a mendelian randomization analysis highlights tentative relevance of diabetes-related traits.Diabetes Care. 2020; Crossref PubMed Scopus (137) Google Scholar]. Since the increased lung ACE2 expression is not equivalent to the susceptibility or disease severity of COVID-19, future MR studies on COVID-19 patients with well-defined phenotypes of disease outcomes will be more directly informative to prioritize treatment candidates. Finally, it has to be noted that it may be challenging in MR studies to choose the correct genetic instruments to model the effects of certain drugs, especially for drugs with multiple targets or mechanisms not fully known. The retrospective design but prospective nature of MR renders its unique advantage during pandemic, which has the potential to dramatically accelerate the translation of epidemiological studies into insights of pathophysiology and targeted therapies in COVID-19. Besides, the advances in genetics provides additional opportunities to promote disease risk prediction through genetic risk scores (GRS), which have been shown effective for CAD risk prediction [[4]Assimes TL Roberts R Genetics: implications for prevention and management of coronary artery disease.J Am Coll Cardiol. 2016; 68: 2797-2818Crossref PubMed Scopus (77) Google Scholar]. Recently, collaborative sequencing projects have been launched to search for human genetic variants that associate with the diverse clinical outcomes of COVID-19 [[10]Kaiser J. How sick will the coronavirus make you? The answer may be in your genes.Science. 2020; (Date last updated: March 27, 2020. Date last accessed: May 10, 2020)https://www.sciencemag.org/news/2020/03/how-sick-will-coronavirus-make-you-answer-may-be-your-genesCrossref Google Scholar], which may contribute to genetic risk prediction of disease severity and exploration of potential drug targets of COVID-19 in the future. Genetics studies hold promise to provide advanced tools in our battle against the COVID-19 pandemic. This work was supported by the National Key Research and Development Program of China (Grant no. 2016YFC0901500) and Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (Grant no. 2017PT31006)." @default.
• W3036706858 created "2020-06-25" @default.
• W3036706858 creator A5054510847 @default.
• W3036706858 creator A5062226704 @default.
• W3036706858 creator A5067484499 @default.
• W3036706858 creator A5073931873 @default.
• W3036706858 creator A5086949270 @default.
• W3036706858 date "2020-07-01" @default.
• W3036706858 modified "2023-10-11" @default.
• W3036706858 title "Mendelian randomization in COVID-19: Applications for cardiovascular comorbidities and beyond" @default.
• W3036706858 cites W2116205322 @default.
• W3036706858 cites W2561460915 @default.
• W3036706858 cites W2829328274 @default.
• W3036706858 cites W3012454642 @default.
• W3036706858 cites W3013302817 @default.
• W3036706858 cites W3022549842 @default.
• W3036706858 cites W3024667276 @default.
• W3036706858 cites W3025926002 @default.
• W3036706858 cites W4255815262 @default.
• W3036706858 doi "https://doi.org/10.1016/j.ebiom.2020.102847" @default.
• W3036706858 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7305723" @default.
• W3036706858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32574960" @default.
• W3036706858 hasPublicationYear "2020" @default.
• W3036706858 type Work @default.
• W3036706858 sameAs 3036706858 @default.
• W3036706858 citedByCount "5" @default.
• W3036706858 countsByYear W30367068582020 @default.
• W3036706858 countsByYear W30367068582021 @default.
• W3036706858 crossrefType "journal-article" @default.
• W3036706858 hasAuthorship W3036706858A5054510847 @default.
• W3036706858 hasAuthorship W3036706858A5062226704 @default.
• W3036706858 hasAuthorship W3036706858A5067484499 @default.
• W3036706858 hasAuthorship W3036706858A5073931873 @default.
• W3036706858 hasAuthorship W3036706858A5086949270 @default.
• W3036706858 hasBestOaLocation W30367068581 @default.
• W3036706858 hasConcept C104317684 @default.
• W3036706858 hasConcept C116675565 @default.
• W3036706858 hasConcept C126322002 @default.
• W3036706858 hasConcept C135763542 @default.
• W3036706858 hasConcept C159047783 @default.
• W3036706858 hasConcept C177713679 @default.
• W3036706858 hasConcept C2778137277 @default.
• W3036706858 hasConcept C2779134260 @default.
• W3036706858 hasConcept C2779159551 @default.
• W3036706858 hasConcept C2779473830 @default.
• W3036706858 hasConcept C2779901538 @default.
• W3036706858 hasConcept C2909376813 @default.
• W3036706858 hasConcept C2993967602 @default.
• W3036706858 hasConcept C3006700255 @default.
• W3036706858 hasConcept C3007834351 @default.
• W3036706858 hasConcept C3008058167 @default.
• W3036706858 hasConcept C524204448 @default.
• W3036706858 hasConcept C54355233 @default.
• W3036706858 hasConcept C55493867 @default.
• W3036706858 hasConcept C60644358 @default.
• W3036706858 hasConcept C70721500 @default.
• W3036706858 hasConcept C71924100 @default.
• W3036706858 hasConcept C86803240 @default.
• W3036706858 hasConcept C89623803 @default.
• W3036706858 hasConceptScore W3036706858C104317684 @default.
• W3036706858 hasConceptScore W3036706858C116675565 @default.
• W3036706858 hasConceptScore W3036706858C126322002 @default.
• W3036706858 hasConceptScore W3036706858C135763542 @default.
• W3036706858 hasConceptScore W3036706858C159047783 @default.
• W3036706858 hasConceptScore W3036706858C177713679 @default.
• W3036706858 hasConceptScore W3036706858C2778137277 @default.
• W3036706858 hasConceptScore W3036706858C2779134260 @default.
• W3036706858 hasConceptScore W3036706858C2779159551 @default.
• W3036706858 hasConceptScore W3036706858C2779473830 @default.
• W3036706858 hasConceptScore W3036706858C2779901538 @default.
• W3036706858 hasConceptScore W3036706858C2909376813 @default.
• W3036706858 hasConceptScore W3036706858C2993967602 @default.
• W3036706858 hasConceptScore W3036706858C3006700255 @default.
• W3036706858 hasConceptScore W3036706858C3007834351 @default.
• W3036706858 hasConceptScore W3036706858C3008058167 @default.
• W3036706858 hasConceptScore W3036706858C524204448 @default.
• W3036706858 hasConceptScore W3036706858C54355233 @default.
• W3036706858 hasConceptScore W3036706858C55493867 @default.
• W3036706858 hasConceptScore W3036706858C60644358 @default.
• W3036706858 hasConceptScore W3036706858C70721500 @default.
• W3036706858 hasConceptScore W3036706858C71924100 @default.
• W3036706858 hasConceptScore W3036706858C86803240 @default.
• W3036706858 hasConceptScore W3036706858C89623803 @default.
• W3036706858 hasFunder F4320323137 @default.
• W3036706858 hasFunder F4320335777 @default.
• W3036706858 hasLocation W30367068581 @default.
• W3036706858 hasLocation W30367068582 @default.
• W3036706858 hasLocation W30367068583 @default.
• W3036706858 hasOpenAccess W3036706858 @default.
• W3036706858 hasPrimaryLocation W30367068581 @default.
• W3036706858 hasRelatedWork W2420168943 @default.
• W3036706858 hasRelatedWork W3003901880 @default.
• W3036706858 hasRelatedWork W3004826915 @default.
• W3036706858 hasRelatedWork W3005417802 @default.
• W3036706858 hasRelatedWork W3007868867 @default.
• W3036706858 hasRelatedWork W3016721635 @default.
• W3036706858 hasRelatedWork W3020699490 @default.
• W3036706858 hasRelatedWork W3031607536 @default.

• next